Response to treatment · patients with schizophrenia
FLUPHENAZINE showed no clear difference in response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
FLUPHENAZINE showed no clear difference in acceptability of treatment‐leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with schizophrenia
FLUPHENAZINE showed no clear difference in adverse effects‐at least one adverse effect compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
1 finding from 1 review
Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia
FLUPHENAZINE may leads to higher adverse effects‐movement disorders‐at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
FLUPHENAZINE leads to lower adverse effects‐other‐sedation compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (high certainty).
1 finding from 1 review
Adverse effects‐death · patients with schizophrenia
1 finding from 1 review
Quality of life · patients with schizophrenia
1 finding from 1 review
Death ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANAOTE changes relapse compared with FLUPHENAZINE ENANTHATE (very low certainty).
1 finding from 1 review
Clinically significant change in global state ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admission ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANAOTE changes leaving the study early compared with FLUPHENAZINE ENANTHATE (very low certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANAOTE changes extrapyramidal adverse effects ‐ general compared with FLUPHENAZINE ENANTHATE (very low certainty).
1 finding from 1 review
Global state: Not improved or worsened ‐ medium term Dichotomised Montgomery‐Asberg Depression Rating Scale (MDRS) · patients with schizophrenia
It is very uncertain whether ORAL FLUPHENAZINE changes global state: Not improved or worsened ‐ medium termDichotomised… compared with PLACEBO (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether ORAL FLUPHENAZINE changes global state: Relapse ‐ long termClinical judgement compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: Death ‐ long termOccurrences of death · patients with schizophrenia
ORAL FLUPHENAZINE showed no clear difference in adverse effects: Death ‐ long termOccurrences of death compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (akathisia) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (rigidity) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review